Gene · 64115
Papers2,513
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
141 to 160 of 2,513
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Targeting myeloid cells to improve cancer immune therapy. | Front Immunol | 2025 | 40821795 | PubTator, text mining | PubMed |
| ROSIE: AI generation of multiplex immunofluorescence staining from histopathology images. | Nat Commun | 2025 | 40819165 | PubTator, text mining | PubMed |
| Exploring IgSF11 as a potential immune checkpoint and immunotherapeutic target in breast cancer. | Cancer Immunol Immunother | 2025 | 40810781 | PubTator, text mining | PubMed |
| Comprehensive analysis of regulatory B Cell related genes in prognosis and therapeutic response in lung adenocarcinoma. | Front Immunol | 2025 | 40808964 | PubTator, text mining | PubMed |
| Pan-cancer landscape of basement membrane: multi-omics research and single-cell sequencing validation. | Cell Cycle | 2025 | 40799172 | PubTator, text mining | PubMed |
| Emerging IO checkpoints in gastrointestinal oncology. | Front Immunol | 2025 | 40777027 | PubTator, text mining | PubMed |
| Immune Modulatory Effects of PD-1/PD-L1 in Myasthenia Gravis: Insights From Peripheral Blood Mononuclear Cell Analysis. | FASEB J | 2025 | 40748491 | PubTator, text mining | PubMed |
| Galectin-9: diverse roles in skin disease. | Front Allergy | 2025 | 40741333 | PubTator, text mining | PubMed |
| Immune evasion in cancer: mechanisms and cutting-edge therapeutic approaches. | Signal Transduct Target Ther | 2025 | 40739089 | PubTator, text mining | PubMed |
| The importance of tumor microenvironment modulations in the progression of pancreatic intraductal papillary mucinous neoplasms. | J Pathol | 2025 | 40736369 | PubTator, text mining | PubMed |
| Hydnocarpin, a Natural Flavonolignan, Induces the ROS-Mediated Apoptosis of Ovarian Cancer Cells and Reprograms Tumor-Associated Immune Cells. | Antioxidants (Basel) | 2025 | 40722951 | PubTator, text mining | PubMed |
Spatial Evaluation and Prognostic Significance of V-Domain Immunoglobulin Suppressor of T-Cell Activation (VISTA) in Human Resectable Cervical Carcinoma: Implications for Immune Activation and Suppression. | Mod Pathol | 2025 | 40716753 | PubTator, text mining | PubMed |
| Modeling cellular influence delineates functionally relevant cellular neighborhoods in primary and metastatic pancreatic ductal adenocarcinoma. | bioRxiv | 2025 | 40667118 | PubTator, text mining | PubMed |
| Aberrant Expression of BTLA, CD160, SPN, TIM-3, VISTA and TIGIT in Chronic Lymphocytic Leukemia and Psoriasis Patients Compared to Healthy Volunteers. | Cancers (Basel) | 2025 | 40647414 | PubTator, text mining | PubMed |
| Targeting mTORC2 in lung squamous cell carcinoma improves anti-tumor immunity through the PSGL-1-VISTA axis. | Cancer Gene Ther | 2025 | 40640525 | PubTator, text mining | PubMed |
| The AML immune paradox: decoding escape pathways and pioneering checkpoint, vaccine, and combination strategies. | Clin Exp Med | 2025 | 40634759 | PubTator, text mining | PubMed |
Overexpression of CTLA-4 and fibronectin, and lower expression of CD137 (4-1BB) is associated with brain metastasis of primary skin melanomas. An analysis of local immune response by digital spatial profiling. | Front Immunol | 2025 | 40621453 | PubTator, text mining | PubMed |
| VISTA is a potential target for immunotherapy in B-cell acute lymphoblastic leukemia in children. | Sci Rep | 2025 | 40610562 | PubTator, text mining | PubMed |
| Negative Immune Checkpoint Inhibitors. | Pharmaceutics | 2025 | 40574024 | PubTator, text mining | PubMed |
| Immune-Checkpoint Expression in Breast Cancer Patients: Clinicopathological Implications: A Retrospective Case Series Study. | Int J Mol Sci | 2025 | 40565313 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/64115/papers?page=8